Colorectal Cancer Screening in Cystic Fibrosis
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy. The primary endpoint is detection of any adenomas, including advanced adenomas and colorectal cancer (CRC).
Checked against the public recordLast updated Mar 24, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
- Interventions being studied
- Procedure: Stool tests
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Adults with CF ages 18 - 75 years and due for a routine screening or surveillance colonoscopy for colon cancer 2. Cystic Fibrosis diagnosis, defined by a sweat chloride test result ≥ 60 mmol/L (may be of historic value), and/or documented CF-causing CFTR mutations and clinical features of CF 3. Capable of understanding the purposes and risks of the study in English or Spanish and willing to participate and sign informed consent 4. Referred for screening or surveillance colonoscopy for CRC (current standard of care) and willing to undergo colonoscopy and stool testing 5. Able to access the Internet to complete self-administered surveys Exclusion Criteria: 1. Any condition that, in the opinion of the site PI, introduces undue risk by participating in this study 2. Incapable of understanding the purposes of the study or informed consent for any reason 3. Pregnancy 4. Active inflammatory bowel disease as defined by a prior diagnosis of Crohn's Disease or Ulcerative Colitis, based on both clinical and histopathologic findings and the individual currently on medical therapy for Crohn's disease or Ulcerative Colitis. 5. Personal history of colon cancer diagnosis and treatment within 5 years of enrollment 6. Symptoms that merit colonoscopy for diagnostic purposes rather than as screening for CRC 7. Known history of familial colon cancer syndrome that has been confirmed by previous genetic testing
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of California, Los AngelesLos Angeles, California
- Stanford University Medical CenterPalo Alto, California
- National Jewish Health, University of ColoradoDenver, Colorado
- University of Miami HospitalMiami, Florida
- University of Kansas Medical CenterKansas City, Kansas
- Johns Hopkins Hospital, Johns Hopkins UniversityBaltimore, Maryland
- Massachusetts General HospitalBoston, Massachusetts
- Boston Children's HospitalBoston, Massachusetts
- Michigan Medicine - University of MichiganAnn Arbor, Michigan
- University of MinnesotaMinneapolis, Minnesota
- Saint Louis UniversitySt Louis, Missouri
- Washington UniversitySt Louis, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 24, 2026. Always confirm current availability with the study team.